[Skip to Content]
[Skip to Content Landing]
March 3, 2010

Modeling Cardiovascular Disease Prevention

JAMA. 2010;303(9):835. doi:10.1001/jama.2010.188

To the Editor: In their Commentary, Drs Hingorani and Psaty1 invoked the prevention paradox (a large proportion of cardiovascular disease [CVD] events occur among the many individuals with average risk factor values) in their discussion of whether to embrace new CVD risk markers as tools for targeting or personalizing statin therapy. They also described another well-known apparent paradox: even risk markers that are strongly associated with the outcome of interest (relative risks of 3 to 5 or even larger) often seem to contribute little in terms of discrimination or reclassification.2

First Page Preview View Large
First page PDF preview
First page PDF preview